Misplaced Pages

#434565

40-402: It is often combined with rituximab . In this case it is called R-EPOCH or EPOCH-R .The R-EPOCH regimen consists of: This regimen requires the use of prophylactic antibiotics to prevent infectious complications, as well as the use of colony-stimulating factors (G-CSF) from the first day after the end of chemotherapy to the day of full blood count restoration ( ANC > 1000/μL). There

80-492: A health system . The list is frequently used by countries to help develop their own local lists of essential medicines . As of 2016 , more than 155 countries have created national lists of essential medicines based on the World Health Organization's model list. This includes both developed and developing countries. The list is divided into core items and complementary items. The core items are deemed to be

120-506: A 2006 study), type 1 diabetes mellitus , Sjögren syndrome , anti-NMDA receptor encephalitis and Devic's disease ( Anti-AQP4 disease , MOG antibody disease ), Graves' ophthalmopathy , autoimmune pancreatitis , Opsoclonus myoclonus syndrome (OMS), and IgG4-related disease . There is some evidence that it is ineffective in treating IgA-mediated autoimmune diseases. Serious adverse events, which can cause death and disability, include: A concern with continuous rituximab treatment

160-421: A blood cancer); chronic lymphocytic leukemia (CLL, another blood cancer affecting white blood cells); severe rheumatoid arthritis (an inflammatory condition of the joints); two inflammatory conditions of blood vessels known as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA); moderate to severe pemphigus vulgaris, an autoimmune disease characterised by widespread blistering and erosion of

200-620: A dose of 375 mg/m2 as per the Lymphome Malin B scheme. Rituximab was approved for medical use in the United States in November 1997. Biosimilars are approved in the United States, India, the European Union, Switzerland, Japan, and Australia. The US FDA approved rituximab-abbs (Truxima) in 2018, rituximab-pvvr (Ruxience) in 2019, and rituximab-arrx (Riabni) in 2020. In July 2024,

240-460: A formulation for subcutaneous injection for B-cell CLL/lymphoma (CLL). In June 2017, the US FDA granted regular approval to the combination of rituximab and hyaluronidase human (brand name Rituxan Hycela) for adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. The combination is not indicated for the treatment of non-malignant conditions. The combination

280-710: A person's small blood vessels become inflamed, reducing the amount of blood that can flow through them. This can cause serious problems and damage to organs, most notably the lungs and the kidneys. It also can impact the sinuses and skin. Rituximab was approved by the FDA to treat adults with granulomatosis with polyangiitis and microscopic polyangiitis in 2011. In December 2021, the US FDA approved rituximab in combination with chemotherapy for children aged 6 months to 18 years with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia. Efficacy

320-539: A result of a disulfide bond between amino acids 167 and 183. Rituximab was developed by IDEC Pharmaceuticals under the name IDEC-C2B8. The US patent for the drug was issued in 1998 and expired in 2015. Based on its safety and effectiveness in clinical trials , rituximab was approved by the US Food and Drug Administration (FDA) in 1997 to treat B-cell non-Hodgkin lymphomas resistant to other chemotherapy regimens. Rituximab, in combination with CHOP chemotherapy ,

360-543: A type of non-Hodgkin lymphoma. Rituximab in combination with hyaluronidase human, sold under the brand names Mabthera SC and Rituxan Hycela, is used to treat follicular lymphoma , diffuse large B-cell lymphoma , and chronic lymphocytic leukemia. It is used in combination with fludarabine and cyclophosphamide to treat previously untreated and previously treated CD20-positive chronic lymphocytic leukemia. Rituximab has been shown to be an effective rheumatoid arthritis treatment in three randomised controlled trials and

400-420: A week a full blood count with white blood cell count (WBC) differential is obtained. Dose escalation above the starting doses in case of good patient's chemotherapy tolerability applies simultaneously to etoposide, doxorubicin and cyclophosphamide. Dose de-escalation below the starting doses in case of poor patient's chemotherapy tolerability applies to cyclophosphamide only. If the nadir ANC > 500/μL, then

440-467: Is 24% less than Rituxan. Dr Reddy's rituximab ituxredi retails for under 10,000 rupees ($ 118) per 100 mg in India. Tailored-dose rituximab is more cost-effective than fixed-dose. It is both more effective and less expensive. Rituximab has been reported as a possible cofactor in a chronic hepatitis E infection in a person with lymphoma. Hepatitis E infection is normally an acute infection, suggesting

SECTION 10

#1733092589435

480-548: Is a chimeric monoclonal antibody targeted against CD20, a surface antigen present on B cells . It acts by depleting normal as well as pathogenic B cells while sparing plasma cells and hematopoietic stem cells , which do not express the CD20 surface antigen. In the United States, rituximab is indicated to treat: In the European Union, rituximab is indicated for the treatment of follicular lymphoma and diffuse large B cell non-Hodgkin's lymphoma (two types of non-Hodgkin's lymphoma,

520-447: Is also an improved version of the regimen. In this version the chemotherapy dose varies from cycle to cycle depending on the patient's ability to tolerate chemotherapy and the degree of neutropenia and thrombocytopenia observed in this patient after each cycle. This approach is called "dose-adjusted EPOCH", or "DA-EPOCH" (DA-EPOCH-R, DA-R-EPOCH or R-DA-EPOCH are used when rituximab is included). Dose change rules are as follows: Twice

560-420: Is given by slow intravenous infusion (injected slowly through an IV line). The most common side effects with intravenous infusions are reactions related to the infusion (such as fever, chills and shivering) while most common serious side effects are infusion reactions, infections and heart-related problems. Similar side effects are seen when it is injected under the skin, with the exception of reactions around

600-506: Is licensed for use in combination with methotrexate in patients with severe active RA who have had an inadequate response to one or more anti-TNF therapy. There is some evidence for efficacy, but not necessarily safety , in a range of other autoimmune diseases, and rituximab is widely used off-label to treat difficult cases of multiple sclerosis , systemic lupus erythematosus , chronic inflammatory demyelinating polyneuropathy and autoimmune anemias . The most dangerous, although among

640-408: Is now licensed for use in refractory rheumatoid disease. In the United States, it has been FDA approved for use in combination with methotrexate for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more anti- TNF-alpha therapy. In the European Union, the license is slightly more restrictive: it

680-408: Is relatively ineffective in elimination of cells with low CD20 cell-surface levels. It tends to stick to one side of B cells, where CD20 is, forming a cap and drawing proteins over to that side. The presence of the cap changes the effectiveness of natural killer (NK) cells in destroying these B cells. When an NK cell latched onto the cap, it had an 80% success rate at killing the cell. In contrast, when

720-551: Is superior to CHOP alone in the treatment of diffuse large B-cell lymphoma and many other B-cell lymphomas. In 2010, it was authorized by the European Commission for maintenance treatment after initial treatment of follicular lymphoma . It is on the World Health Organization's List of Essential Medicines . Originally available for intravenous injection (e.g. over 2.5 hrs), in 2016, it gained EU approval in

760-479: Is the difficulty to induce a proper vaccine response. This was brought into focus during the COVID-19 pandemic , where persons with multiple sclerosis and rituximab treatment had higher risk of severe COVID-19. In persons previously treated with rituximab for multiple sclerosis, nine of ten patients who delayed re-dosing until B cell counts passed 40/μL developed protective levels of antibodies after vaccination with

800-419: Is under study. The efficacy and success of rituximab has led to some other anti-CD20 monoclonal antibodies being developed: WHO Model List of Essential Medicines The WHO Model List of Essential Medicines (aka Essential Medicines List or EML ), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in

840-574: The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of marketing authorization to Dr. Reddy's Laboratories / Holding GmbH for their rituximab biosimilar Ituxredi, intended for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis and pemphigus vulgaris. Ituxredi

SECTION 20

#1733092589435

880-601: The Pfizer–BioNTech COVID-19 vaccine . The antibody binds to the cell surface protein CD20 . CD20 is widely expressed on B cells, from early pre-B cells to later in differentiation , but it is absent on terminally differentiated plasma cells . Although the function of CD20 is unknown, it may play a role in Ca influx across plasma membranes, maintaining intracellular Ca concentration and allowing activation of B cells. Rituximab

920-427: The B cell lacked this asymmetric protein cluster, it was killed only 40% of the time. The following effects have been found: The combined effect results in the elimination of B cells (including the cancerous ones) from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells . Rituximab binds to amino acids 170–173 and 182–185 on CD20, which are physically close to each other as

960-405: The European Union and in the United States. Biosimilars were approved in the United States, India, the European Union, Switzerland, Japan, and Australia. The US FDA approved rituximab-abbs (Truxima) in 2018, rituximab-pvvr (Ruxience) in 2019, and rituximab-arrx (Riabni) in 2020. Truxima and Riabni are approximately $ 3600 per 500 mg, wholesale - 10% less than Rituxan, while Ruxience

1000-487: The brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer . It is used for non-Hodgkin lymphoma , chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis , granulomatosis with polyangiitis , idiopathic thrombocytopenic purpura , pemphigus vulgaris , myasthenia gravis and Epstein–Barr virus -positive mucocutaneous ulcers . It

1040-450: The children's list is also included in the main list. The list and notes are based on the 19th to 23rd edition of the main list. Therapeutic alternatives with similar clinical performance are listed for some medicines and they may be considered for national essential medicines lists. The 9th Essential Medicines List for Children was updated in July 2023. Note: An α indicates a medicine

1080-418: The doses of etoposide, doxorubicin, and cyclophosphamide for the next cycle are all increased by 20% over the doses used in the previous cycle. If the nadir ANC < 500/μL on one or two blood checks, but ANC rises above 500 at the time of third check (i.e. the duration of agranulocytosis is less than nine days), and the nadir of platelet count is > 25,000/μL, then the dose for the next course will remain

1120-613: The drug in combination with lymphoma may have weakened the body's immune response to the virus. In 2009, a patient receiving methotrexate-induced B-cell depletion for cancer treatment, experienced a transient remittal of their myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) symptoms. While initial trials using Rituximab were promising, a phase 3 trial published in 2019 did not find an association between Rituximab treatment and improvements in ME/CFS. For CNS diseases, rituximab could be administered intrathecally and this possibility

1160-430: The injections site (pain, swelling and rash), which occur more frequently with the skin injections. Severe side effects include reactivation of hepatitis B in those previously infected, progressive multifocal leukoencephalopathy , toxic epidermal necrolysis , and death. It is unclear if use during pregnancy is safe for the developing fetus or newborn baby. Rituximab is a chimeric monoclonal antibody against

1200-499: The institutional upper limit of normal values) or stage IV B-cell non-Hodgkin's lymphoma or B-cell acute leukemia. Participants were randomized to Lymphome Malin B chemotherapy that consisted of corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide, and triple drug (methotrexate/cytarabine/corticosteroid) intrathecal therapy alone or in combination with rituximab or non-US licensed rituximab, administered as six infusions of rituximab IV at

1240-497: The list are available as generic products , being under patent does not preclude inclusion. The first list was published in 1977 and included 208 medications. The WHO updates the list every two years. There are 306 medications in the 14th list in 2005, 410 in the 19th list in 2015, 433 in the 20th list in 2017, 460 in the 21st list in 2019, and 479 in the 22nd list in 2021. Various national lists contain between 334 and 580 medications. The Essential Medicines List (EML)

EPOCH (chemotherapy) - Misplaced Pages Continue

1280-437: The most cost-effective options for key health problems and are usable with little additional health care resources. The complementary items either require additional infrastructure such as specially trained health care providers or diagnostic equipment or have a lower cost–benefit ratio . About 25% of items are in the complementary list. Some medications are listed as both core and complementary. While most medications on

1320-662: The most rare, side effect is progressive multifocal leukoencephalopathy infection, which is usually fatal; however, only a very small number of cases have been recorded occurring in autoimmune diseases. Other autoimmune diseases that have been treated with rituximab include autoimmune hemolytic anemia , pure red cell aplasia , thrombotic thrombocytopenic purpura (TTP), idiopathic thrombocytopenic purpura (ITP), Evans syndrome , vasculitis (e.g., granulomatosis with polyangiitis ), bullous skin disorders (for example, pemphigus , pemphigoid —with very encouraging results of approximately 85% rapid recovery in pemphigus, according to

1360-543: The protein CD20 , which is primarily found on the surface of immune system B cells . When it binds to this protein it triggers cell death. Rituximab was approved for medical use in 1997. It is on the World Health Organization's List of Essential Medicines . Rituxan is co-marketed by Biogen and Genentech in the US, by Roche elsewhere except Japan, and co-marketed by Chugai Pharmaceuticals and Zenyaku Kogyo in Japan. Rituximab

1400-402: The same. If the nadir ANC < 500/μL for 10 days or more, or if the nadir platelet count at every time falls below 25,000/μL, then the doses of etoposide, doxorubicin and cyclophosphamide are reduced by 20% below the doses used in the previous cycle, but doxorubicin and etoposide should not be reduced below the initial dose (dose in first course). Rituximab Rituximab , sold under

1440-472: The skin and mucous membranes (the linings of internal organs). 'Autoimmune' means that the disease is caused by the immune system (the body's natural defences) attacking the body's own cells. Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas , including non-Hodgkin's lymphoma, chronic lymphocytic leukemia , and nodular lymphocyte predominant Hodgkin's lymphoma. This also includes Waldenström's macroglobulinemia ,

1480-406: Was approved based on clinical studies SABRINA/NCT01200758 and MabEase/NCT01649856. In September 2019, the US FDA approved rituximab injection to treat granulomatosis with polyangiitis and microscopic polyangiitis in children two years of age and older in combination with glucocorticoids (steroid hormones). It is the first approved treatment for children with these rare vasculitis diseases, in which

1520-471: Was authorized for medical use in the European Union in September 2024. Dr Reddy's Rituximab biosimilar Reditux was approved in India in 2007. In 2014, Genentech reclassified Rituxan as a specialty drug , a class of drugs that are only available through specialty distributors in the US. Because wholesalers discounts and rebates no longer apply, hospitals would pay more. Patents on rituximab have expired in

1560-478: Was evaluated in Inter-B-NHL Ritux 2010, a global multicenter, open-label, randomized 1:1 trial of participants six months in age or older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or B-cell acute leukemia. Advanced stage was defined as stage III with elevated lactose dehydrogenase level (lactose dehydrogenase greater than twice

1600-517: Was updated in July 2023 to its 23rd edition. This list contains 1200 recommendations for 591 drugs and 103 therapeutic equivalents. A separate list for children up to 12 years of age, known as the WHO Model List of Essential Medicines for Children (EMLc), was created in 2007 and is in its 9th edition. It was created to make sure that the needs of children were systematically considered such as availability of proper formulations . Everything in

#434565